
|Videos|September 19, 2017
Dr. Bauml Discusses the FLAURA Study in NSCLC
Author(s)Joshua Bauml, MD
Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the FLAURA trial in patients with EGFR-mutant non–small cell lung cancer.
Advertisement
Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the FLAURA trial in patients with EGFR-mutant non—small cell lung cancer (NSCLC).
FLAURA is a randomized phase III study of frontline osimertinib (Tagrisso) compared with either erlotinib (Tarceva) or gefitinib (Iressa).
Results showed an improvement in progression-free survival, and a trend was observed toward overall survival with osimertinib—though it is not yet statistically significant.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5



































